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The Epstein–Barr virus (EBV) nuclear antigen-1 (EBNA-1) is required for the maintenance of the viral chromosome in
latently infected, proliferating cells and plays a role in latent cycle DNA replication. EBNA-1 also functions as a positive and
negative regulator of EBV gene expression. We have investigated the interaction of EBNA-1 with p32, a host mitochondrial
protein that associates with EBNA-1 in EBV-positive Burkitt’s lymphoma cells. Using a chromatin immunoprecipitation assay,
we found that a fraction of p32 localizes to the viral latent cycle origin of DNA replication oriP in vivo. p32 binds EBNA-1
independently of other proteins or DNA. EBNA-1 variants lacking one of two p32 binding elements did not interact stably with
p32 in cultured cells and were defective for both transcriptional activation of a reporter gene linked to oriP FR and replication
and/or maintenance of a plasmid bearing oriP. These results support a role for p32 in transcriptional activation by EBNA-1
and suggest that p32 plays a role in EBV latent cycle DNA replication. © 2000 Academic PressINTRODUCTION
Epstein–Barr virus (EBV) has attracted much attention
because of its ability to establish latency in resting B
lymphocytes (Miyashita et al., 1997) and its association
with a number of human cancers including nasopharyn-
geal carcinoma, endemic Burkitt’s lymphoma (BL), and
immunoblastic B-cell lymphoma (Rickinson and Kieff,
1996). The viral genome is maintained as a plasmid in
the nucleus of latently infected cells (Lindahl et al., 1976)
nd is replicated once per cell division cycle in parallel
ith replication of the cellular chromosomes (Adams,
987). The EBV latent cycle origin of DNA replication,
riP, supports the efficient replication and maintenance
f recombinant plasmids in EBV-positive cells (Yates et
l., 1984). Notably, the replication of oriP-plasmids is also
ell-cycle-regulated and an origin of DNA replication has
een identified within oriP (Gahn and Schildkraut, 1989).
nly one viral protein, the EBV nuclear antigen-1
EBNA-1), is required for the replication and maintenance
f plasmids bearing oriP (Yates et al., 1985).
oriP contains two clusters of EBNA-1 binding sites (the
amily of repeats, FR, and sites within the dyad symmetry
lement, DS) which are required for the stable mainte-
ance of oriP-plasmids (Lupton and Levine, 1985; Reis-
an et al., 1985). EBNA-1 plays a crucial role in the
maintenance of viral DNA in dividing cells through its
1 Present address: Division of Molecular Neurobiology, National In-
titute for Basic Biology, Okazaki, Japan.2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (631) 632-9797. E-mail: jhearing@ms.cc.sunysb.edu.
145interaction with FR (Aiyar et al., 1998). Derivatives of
oriP-plasmids that lack FR are replicated but not retained
in cells (Aiyar et al., 1998; Harrison et al., 1994; Shirakata
and Hirai, 1998). The mechanism(s) by which EBV ge-
nomes are retained in cells and partitioned equally dur-
ing cell division is not known but plasmid retention may
involve the association of EBNA-1 and the EBV genome
with cellular chromosomes during mitosis (Grogan et al.,
1983; Harris et al., 1985). EBNA-1 self-associates through
multiple “linking” domains (Laine and Frappier, 1995;
Mackey et al., 1995). These interactions allow EBNA-1 to
bring FR and DS together and loop the intervening DNA
in vitro (Frappier and O’Donnell, 1991a; Su et al., 1991)
and may underlie the association of oriP-plasmids with
cellular chromosomes (Aiyar et al., 1998).
EBNA-1 is not required for the transient replication of
plasmids bearing DS but the presence of EBNA-1 in-
creases the likelihood that they will be replicated (Aiyar
et al., 1998). The inability of EBNA-1 to unwind DNA in
oriP (Frappier and O’Donnell, 1992; Hearing et al., 1992)
distinguishes EBNA-1 from other eukaryotic viral origin
recognition proteins which are DNA helicases (Bruckner
et al., 1991; Stahl et al., 1986; Yang et al., 1993) and
indicates that EBNA-1 must facilitate the synthesis of
oriP-plasmids by a different mechanism. EBNA-1 inter-
acts with replication protein A in vitro (Zhang et al., 1998)
and this result suggests a direct role for EBNA-1 in the
initiation of EBV latent cycle DNA replication.
An acidic cellular protein termed p32 was originally
identified and cloned on the basis of its copurification
with the human pre-mRNA splicing factor SF2/ASF
(Krainer et al., 1991). p32 has been implicated in pre-
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146 VAN SCOY ET AL.mRNA splicing (Petersen-Mahrt et al., 1999), transcrip-
tional activation by HIV-1 Tat (Yu et al., 1995b), HIV-1 Rev
function (Luo et al., 1994), and gC1q receptor activity
(Ghebrehiwet et al., 1994), among other putative func-
tions. p32 was also shown to interact with EBNA-1 in
yeast and in human cells transiently expressing EBNA-1
(Wang et al., 1997). p32 is synthesized as a 282-amino-
acid-long polypeptide and most p32 is posttranslationally
imported into mitochondria by an amino-terminal target-
ing sequence which is later removed (Matthews and
Russell, 1998; Muta et al., 1997; Seytter et al., 1998). The
mature protein crystallizes as a doughnut-shape ho-
motrimer with a striking asymmetric distribution of
charged residues (Jiang et al., 1999). Although mostly
mitochondrial, p32 has been detected in the nucleus of
human A549 cells by confocal microscopy (Matthews
and Russell, 1998). p32 binds two regions of EBNA-1 and
derivatives lacking these interaction elements are defec-
tive for the transcriptional activation of a reporter gene
linked to FR (Wang et al., 1997). Here we show that a
fraction of p32 is localized to oriP in EBV-positive BL cells
and demonstrate that EBNA-1 interacts with p32 inde-
pendently of other proteins or DNA. EBNA-1 variants that
lack one of the two p32 binding elements are defective
for the stable interaction with p32 in vivo, transcriptional
activation, and the replication and/or maintenance of a
plasmid bearing oriP. These results provide further evi-
dence supporting a role for p32 in the activation of
transcription by EBNA-1 and suggest a role for p32 in
EBV genome replication and/or maintenance.
RESULTS
EBNA-1 and p32 interact in EBV-positive Burkitt’s
lymphoma cells
p32 was identified as an EBNA-1-interacting host pro-
tein in yeast two-hybrid screens (Aiyar et al., 1998; Wang
et al., 1997) and in coimmunoprecipitation experiments
performed with 293 cells transiently expressing EBNA-1
(Wang et al., 1997). To determine whether the interaction
of endogenous EBNA-1 and p32 could be detected in
cells latently infected with EBV, extracts prepared from
EBV-positive (Raji and Akata) and -negative (Louckes) BL
cells were immunoprecipitated with a rabbit anti-EBNA-1
serum or preimmune serum and the precipitated pro-
teins were examined by blotting with anti-p32 antibodies
(Fig. 1A). p32 was present in the anti-EBNA-1 precipi-
tates from Raji and Akata cell extracts and absent from
the anti-EBNA-1 precipitate from the Louckes cell extract
and precipitates formed with preimmune serum. p32 also
coprecipitated with EBNA-1 from extracts prepared from
293 cells infected with an EBNA-1-expressing adenovi-
rus, but not cells infected with a control virus, and from
COS-7 cells expressing EBNA-1 transiently from a plas-
mid vector (Figs. 1B and 1C). Monkey p32 from COS-7
cells migrated more rapidly on SDS–gels than humanp32 (data not shown) allowing the clear differentiation of
a nonspecifically precipitated polypeptide (Figs. 1A and
1B) from p32. These results confirm the previously re-
ported interaction of EBNA-1 and p32 in 293 cell extracts
(Wang et al., 1997) and further show that an EBNA-1–p32
complex may be detected in extracts prepared from
EBV-positive BL cells.
Specificity and mechanism of interaction
Because p32 binds two regions of EBNA-1 containing
arginine- and glycine-rich repeats (Wang et al., 1997) and
FIG. 1. Detection of EBNA-1–p32 complex(es) in animal cells. (A)
Preimmune (P) or immune (I) serum precipitates prepared from
Louckes (lanes 2 and 3), Raji (lanes 4 and 5), and Akata (lanes 6 and
7) extracts were analyzed by blotting with chicken antibodies to p32. A
whole-cell extract prepared from Raji cells (1 3 106; lane 1) shows the
position of p32. (B) Extracts prepared from 293 cells infected with either
Ad dl356-E2-CAT-LSATF (lanes 1 and 2) or Ad/CMV-EBNA1 (lanes 3 and
4) were subjected to precipitation with rabbit preimmune serum (P) or
anti-EBNA-1 serum (I). Precipitates and whole cell extracts prepared
from 1 3 106 293 (lane 5) or Raji (lane 6) cells were analyzed by
mmunoblotting for p32 as in (A). (C) COS-7 cells were mock-trans-
ected (lane 1) or transfected with an EBNA-1 expression plasmid
p371; lane 2), and extracts prepared 38 h later were immunoprecipi-
ated with rabbit anti-EBNA-1 serum. Precipitates were analyzed by
lotting as in (A).p32 is acidic (calculated pI of 4.57 and 4.15 for residues
1–282 and 74–282, respectively), we considered the pos-
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147EBNA-1 RECRUITS p32 TO oriPsibility that the interaction between EBNA-1 and p32
represented the nonspecific binding of proteins with op-
posite charges. To investigate the specificity of the inter-
action of p32 with EBNA-1, we tested whether p32 could
interact with other arginine-rich proteins. The product of
the herpes simplex virus type 1 Us11 gene binds 60S
ibosomal RNA, and the RNA binding domain has been
ocalized to the carboxy-terminal half of the protein (Roll-
r et al., 1996). This region of Us11 (residues 79–161) is
omposed of a tripeptide repeat, Arg-X-Pro. GST/Us11(1–
161)-beads did not, however, precipitate p32 from a HeLa
cell extract (data not shown). Additionally, the carboxy-
terminus of hepatitis B virus core antigen is arginine-rich
(17/36 residues) and this protein did not interact detect-
ably with p32 in a yeast two-hybrid assay (Bartel et al.,
1993). This selectivity indicates that the interaction of p32
with EBNA-1 may not be explained as the irrelevant
interaction of an acidic protein with arginine-rich pro-
teins.
Although yeast two-hybrid assays (Aiyar et al., 1998;
Wang et al., 1997) and coprecipitation experiments
Wang et al., 1997; Fig. 1) demonstrated an interaction
etween EBNA-1 and p32 independent of other EBV
ene products, they could not distinguish between a
irect or indirect interaction. To distinguish between
hese possibilities, an immunoprecipitation experiment
as performed with purified proteins (Fig. 2). In agree-
ent with the data in Fig. 1, p32 was precipitated by
nti-EBNA-1 antibodies in the presence but not the ab-
ence of EBNA-1. Pretreatment of EBNA-1 and p32 with
thidium bromide to inhibit DNA-dependent protein in-
eractions (Lai and Herr, 1992) or ribonuclease A (RNase
FIG. 2. Formation of an EBNA-1–p32 complex in the absence of other
roteins and DNA. Highly purified EBNA-1 and recombinant p32 were
ncubated in the presence of ethidium bromide (lane 5) or RNase A
lane 6) or alone (lane 4), combined, and precipitated with rabbit
nti-EBNA-1 serum. Immunoprecipitations were also performed with
32 alone (lane 2), EBNA-1 alone (lane 3), or neither protein (lane 1).
mmunoprecipitates and an extract prepared from Raji cells (lane 7)
ere analyzed by blotting with chicken antibodies to p32. Rabbit im-
unoglobulin (Ig) heavy chains that reacted with HRP-conjugated rab-
it anti-chicken antibodies in lanes 1–6 are indicated.) to degrade any contaminating RNA did not prevent the
oprecipitation of EBNA-1 and p32. Therefore, the inter-action of EBNA-1 and p32 does not require additional
proteins or DNA. Because RNase A cannot hydrolyze
double-stranded RNA, it is possible that the interaction of
EBNA-1 and p32 is mediated by binding of each protein
to a piece of double-stranded RNA. However, p32 has not
been observed to bind RNA (Petersen-Mahrt et al., 1999;
ange et al., 1996), making this explanation unlikely.
32 associates with oriP in Raji cells
To determine whether p32 localizes to oriP in vivo,
chromatin immunoprecipitation experiments were per-
formed with Raji cells. Intact cells were treated with
formaldehyde to crosslink proteins and nucleic acids
and chromatin was isolated by isopycnic centrifugation
in CsCl–Sarkosyl (Varshavsky et al., 1979). Purified chro-
atin was immunoprecipitated with antibodies to
BNA-1 or p32 and the precipitated DNA was analyzed
y PCR to detect FR or DS. Each reaction contained a
econd set of primers that allowed detection of a region
f EBV DNA located over 84 kbp from oriP (codons 1–89
f the EBNA-1 open reading frame [orf]) to monitor the
onspecific precipitation of chromatin. PCR analysis of
wofold serial dilutions of the input DNA (Fig. 3C) showed
hat both DS and EBNAorf could be amplified from the
hromatin preparations and these results were used to
FIG. 3. p32 associates with oriP in vivo. (A) Chromatin immunopre-
cipitations were performed with mAb to LFA1 and EBNA-1 (left) and
mAb to HA and p32 (right). Serial dilutions (2.5-fold) of each precipitated
DNA sample (0.25 to 0.04% of total) were analyzed by PCR for the
presence of DS and EBNAorf. (B) Chromatin was immunoprecipitated
with mAb26 ascites fluid preadsorbed with GST- or GST/p32-beads and
analyzed as for (A) except that the amount of mAb used was reduced
100-fold. (C) Twofold serial dilutions of DNA from chromatin used in the
immunoprecipitations (4 to 0.03 ng) were analyzed by PCR for DS and
EBNAorf. Markers (M): pBR322 digested with HinfI.
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148 VAN SCOY ET AL.quantify the amount of input DNA precipitated with var-
ious antibodies.
A monoclonal antibody (mAb) to EBNA-1 (mAb2B4)
enriched DS 73-fold relative to EBNAorf (0.73% of DS and
0.01% of EBNAorf coprecipitated; averages of three ex-
periments), whereas DS was not enriched in immuno-
precipitates prepared with an mAb to an irrelevant anti-
gen (LFA-1; Fig. 3A, left). Chromatin containing DS was
also enriched compared to chromatin containing EB-
NAorf in immunoprecipitates prepared with a rabbit anti-
EBNA-1 serum (1.28% of DS and 0.27% of EBNAorf co-
precipitated) but not with the preimmune serum (less
than 0.03% of DS and EBNAorf coprecipitated) (data not
shown). Ascites fluid containing an anti-p32 mAb
(mAb26) gave a 47-fold enrichment of DS relative to
EBNAorf (average of two experiments; Fig. 3A, right) and
similar results were obtained with three additional anti-
p32 mAbs. All four anti-p32 mAbs which could precipitate
oriP chromatin could precipitate DNA fragments bearing
FR and DS provided that both EBNA-1 and p32 were
present (representative data for mAb26 shown in Fig. 4).
The precipitation of DS chromatin by the four anti-p32
FIG. 4. p32 coprecipitates with EBNA-1 and oriP FR and DS in vitro.
EBNA-1 and p32 (lanes 4–7) were incubated together and then diluted
into buffer containing end-labeled DNA fragments from pBS/oriP. Con-
trol reactions contained p32 alone (lane 2), EBNA-1 alone (lane 3), or
neither protein (lane 1). Following incubation, the reactions were sub-
jected to immunoprecipitation with ascites fluids containing anti-p32
mAb26 (lanes 1–7) and the precipitated DNA was analyzed by agarose
gel electrophoresis and autoradiography. Lanes 4–7 contain increasing
quantities (twofold increments) of the anti-p32 mAb. Input DNA frag-
ments are displayed in the lane labeled M.mAbs was not due to cross reaction with EBNA-1, as they
did not recognize EBNA-1 in immunoblot experiments
a
aand were unable to precipitate FR or DS when bound by
purified EBNA-1 in vitro (Fig. 4 and data not shown).
Furthermore, the precipitation of DS chromatin by mAb26
ascites fluid was specific to the anti-p32 antibody, as
ascites fluid containing mAb to an irrelevant antigen
(aHA) failed to precipitate specifically DS or EBNAorf
Fig. 3A, right) and adsorption of mAb26 ascites fluid with
garose beads coupled to a glutathione S-transferase
GST)–p32(74–282) fusion protein, but not GST-beads,
liminated its ability to precipitate DS chromatin (Fig. 3B).
inally, the rebanding of chromatin on a second CsCl–
arkosyl gradient to eliminate any non-chromatin-bound
32 did not alter the ability of mAb26 to precipitate DS
data not shown). These results demonstrate that p32 is
ocalized to oriP in Raji cells. Qualitatively similar results
ere obtained when immunoprecipitated chromatin was
mplified with FR-specific primers. However, the fold
nrichment of FR compared to EBNAorf could not be
etermined as all primer pairs and PCR conditions
ested failed to yield a linear response to changes in
nput DNA.
uclear localization of p32(74–282) by EBNA-1
Our attempts to detect endogenous p32 in the nuclei
f EBNA-1-expressing cells or control cells by immuno-
luorescence (IF) staining have not been successful.
owever, IF stains of HeLa cells expressing EBNA-1 and
pitope-tagged p32 that lacks the presequence (M45-
32[74–282]) provided an in vivo assay for the interaction
f EBNA-1, and EBNA-1 derivatives deleted for p32 bind-
ng sites, with p32. The expression of M45-p32(74–282) in
eLa cells was generally just visible over background
taining. In one experiment, 31 of approximately 8000
ells present on a coverslip exhibited light cytoplasmic
taining following transfection with an M45-p32(74–282)
xpression plasmid and, rarely (1 cell in this experiment),
ells with faint nuclear fluorescence were observed
Figs. 5A and 5B). Coexpression of EBNA-1 gave both a
ramatic increase in staining intensity and an apparent
hreefold increase in the number of cells expressing
45-p32(74–282). In two-thirds of these cells, M45-
32(74–282) was nuclear or predominantly nuclear, and
he remaining cells exhibited a largely cytoplasmic stain
examples of the first two staining patterns are shown in
ig. 5C). Dual-labeling of cells with antibodies to M45-
32(74–282) and EBNA-1 showed that all cells with in-
reased staining for M45-p32(74–282) expressed
BNA-1 (Fig. 5D).
p32 binds two regions of EBNA-1 containing arginine-
nd glycine-rich repeats (Wang et al., 1997). EBNA-1
ariants lacking either or both p32 binding sites were
reated to investigate the function(s) of oriP-bound p32.
or ease of discussion, the repeat located within amino
cids 33–53 and the two adjacent repeats located within
mino acids 329–382 are referred to as Box A and Box
t
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p32(74–282) in two different fields of cells. The distribution of M45-
p32(74–282) (C, E, G, I, and K) and full-length or mutant EBNA-1 proteins
149EBNA-1 RECRUITS p32 TO oriPB/C. EBNA-1 variants lacking these repeats (deletions of
residues 34–57 and/or 329–376) were derived from
EBNA-1 lacking all but 12 residues of the Gly-Gly-Ala
repeats (EBNA-1Dgly-ala). The Gly-Gly-Ala repeats are
not required for the transcriptional activation and DNA
replication activities of EBNA-1 (Yates and Camiolo,
1988) nor for the interaction of EBNA-1 with p32 in yeast
(Aiyar et al., 1998; Wang et al., 1997). The expression of
hese EBNA-1 derivatives was analyzed by IF staining
Fig. 5) and immunoblotting (Fig. 6). EBNA-1, EBNA-
Dgly-ala, and EBNA-1DBox A were predominantly nu-
lear while EBNA-1DBox B/C and EBNA-1DBox A/B/C,
lthough largely nuclear, could also be detected in the
ytoplasm in some cells. EBNA-1DBoxB/C and EBNA-
DBox A/B/C were also expressed at slightly lower levels
han the other proteins. Yeast two-hybrid experiments
Bartel et al., 1993) demonstrated that EBNA-1DA/B/C
acked the ability to interact with EBNA-1 (data not
(D, F, H, J, and L) in the same cells is shown. Identical results were
FIG. 6. EBNA-1 and derivatives lacking the Gly-Gly-Ala repeats and
Box A and/or Box B/C accumulate to similar levels in the nucleus.
Nuclear (N) and postnuclear (C) extracts were prepared from HeLa
cells transfected with pCMX (lanes 1 and 2), pCMX/EBNA-1 (lanes 3
and 4), pCMX/EBNA-1Dgly-ala (lanes 5 and 6), pCMX/EBNA-1DBox A
(lanes 7 and 8), pCMX/EBNA-1DBox B/C (lanes 9 and 10), or pCMX/
EBNA-1DBox A/B/C (lanes 11 and 12) and analyzed by blotting with
mAb2B4 to detect EBNA-1 and its derivatives (Gra¨sser et al., 1994). The
positions of molecular mass markers are shown on the right.FIG. 5. EBNA-1 coexpression results in the increased nuclear accu-
mulation of epitope-tagged p32(74–282). HeLa cells were cotransfected
with pE1A-CMX/p32(74–282) and pCMX (A and B), pCMX/EBNA-1 (C
and D), pCMX/EBNA-1Dgly-ala (E and F), pCMX/EBNA-1DBox A (G and
H), pCMX/EBNA-1DBox B/C (I and J), or pCMX/EBNA-1DBox A/B/C (K
and L) and IF stains were performed 48 h later with mAb M45 to detect
epitope-tagged p32(74–282) and an anti-EBNA-1 serum. Primary anti-
bodies were detected with FITC-conjugated goat anti-mouse IgG and
TRITC-conjugated goat anti-rabbit IgG. A and B show labeling of M45-obtained with a mouse mAb to EBNA-1 that recognizes an epitope in
the DNA binding domain (Orlowski et al., 1990) and with NIH 3T3 cells.
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150 VAN SCOY ET AL.shown). Coexpression of M45-p32(74–282) with EBNA-
1Dgly-ala or EBNA-1DBox A resulted in the increased
intracellular and intranuclear accumulation of M45-
p32(74–282) (Figs. 5E and 5G). In contrast, EBNA-1DBox
B/C and EBNA-1DBox A/B/C did not have this effect.
Although both EBNA-1DBox B/C and EBNA-1DBox A/B/C
were detected in the nucleus (Figs. 5J and 5L), M45-
p32(74–282) was predominantly cytoplasmic when coex-
pressed with these EBNA-1 derivatives (Figs. 5I and 5K).
These results demonstrate that the nuclear accumula-
tion of M45-p32(74–282) is mediated by its binding to
EBNA-1 and suggest that the two p32 binding sites are
not equivalent in this regard.
EBNA-1 derivatives that lack p32 binding site(s) are
defective for the replication and/or maintenance of an
oriP-plasmid
To determine whether EBNA-1 variants that failed to
cause the nuclear accumulation of M45-p32(74–282)
could support the replication and maintenance of an
oriP-plasmid, Hela cells were cotransfected with pHEBo-
1.1 and an expression plasmid for either EBNA-1 or an
EBNA-1 derivative. pHEBo-1.1 replication and mainte-
FIG. 7. EBNA-1 derivatives lacking amino acids 329–376 are defec-
tive for the short-term replication and/or maintenance of an oriP-
plasmid. HeLa cells were cotransfected with an oriP-plasmid (pHEBo-
1.1) and pCMX (lane 1), pCMX/EBNA-1 (lane 2), pCMX/EBNA-1Dgly-ala
(lane 3), pCMX/EBNA-1DBox A (lane 4), pCMX/EBNA-1DBox B/C (lane
5), or pCMX/EBNA-1DBox A/B/C (lane 6). Low-molecular-weight DNA
was isolated 90 h post transfection, digested with DpnI and ClaI, and
xamined by Southern blotting with a radiolabeled pHEBo-1.1 probe. A
ortion of the gel containing full-length linear plasmid DNA (L), super-
oiled plasmid DNA (SC), and the largest DpnI restriction fragments
bottom) is shown.nance was assayed by Southern blotting of low-molec-
ular-weight DNA digested with DpnI and ClaI (Fig. 7).Input plasmid DNA, isolated from a dam1 Escherichia
coli strain, is digested by DpnI while replicated plasmid
DNA is resistant to DpnI and linearized by ClaI. The
amount of linear DpnI-resistant pHEBo-1.1 DNA detected
in this assay reflects the extent to which plasmids are
both replicated and retained in the cell. Only a small
amount of replicated pHEBo-1.1 was detected 90 h post-
transfection of HeLa cells in the absence of EBNA-1 (not
visible on the film exposure in Fig. 7) and EBNA-1Dgly-
ala supported the stable maintenance of pHEBo-1.1 to a
level similar to EBNA-1 (77 6 19%). The amount of rep-
licated pHEBo-1.1 in HeLa cells expressing EBNA-1DBox
A, EBNA-1DBox B/C, and EBNA-1DBox A/B/C was 65 6
5, 4 6 1, and 3 6 2%, respectively, the amount observed
in the presence of EBNA-1 after four cell generations. If
the amount of replicated plasmid DNA detected in these
experiments was due to inefficient initiation of DNA rep-
lication and one assumes that plasmids that were not
replicated in one S phase were present in the daughter
cell nuclei in the subsequent S phase, the efficiency of
pHEBo-1.1 replication supported by EBNA-1 derivatives
lacking amino acids 34–57, 329–376, or 34–57 and 329–
376 per cell generation was 80-, 8-, and 6%, respectively,
compared to EBNA-1. If, however, replication of the plas-
mids occured once per S phase and the reduced amount
of replicated plasmid DNA detected in these experi-
ments was the result of inefficient maintenance of the
DNA, the efficiency of plasmid DNA retention supported
by EBNA-1 derivatives lacking amino acids 34–57 or
329–376 per cell generation was 90 and 45%, respec-
tively, compared to EBNA-1. These results show that
regions of EBNA-1 that bind p32 are required for the
efficient initiation of DNA replication of oriP plasmids
and/or their retention in HeLa cells and that deletion of
amino acids 329–376 had a greater effect than deletion
of amino acids 34–57.
EBNA-1 derivatives that lack p32 binding sites are
defective for transcriptional activation
It was previously reported that EBNA-1 deleted for
amino acids 40–60 and all the Gly-Gly-Ala repeats did
not activate expression of a reporter gene linked to FR
(Wang et al., 1997). Because a similar deletion (amino
acids 34–57) had only a small effect on oriP-plasmid
replication and/or maintenance (Fig. 7) and previous
genetic analyses of EBNA-1 have been unable to sepa-
rate its transcription and replication functions (Yates and
Camiolo, 1988), the transcriptional activation function of
EBNA-1 derivatives lacking p32 binding site(s) described
above was analyzed (Table 1). EBNA-1 and EBNA-1Dgly-
ala increased expression of a reporter gene in human
143 cells and mouse NIH 3T3 cells in an FR-dependent
manner and to a similar extent (Table 1; data not shown).
The level of transactivation for EBNA-1DBox A was 81%
of the level observed with EBNA-1Dgly-ala in 143 cells
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151EBNA-1 RECRUITS p32 TO oriPand 58% of the level observed with EBNA-1Dgly-ala in
NIH 3T3 cells. In contrast, EBNA-1 derivatives lacking
Box B/C were markedly defective for transcriptional ac-
tivation. This defect was most apparent in NIH 3T3 cells
where EBNA-1DBox B/C and EBNA-1DBox A/B/C only
activated luciferase expression from FR-TK-luc 6 and 4%,
respectively, of the level observed with EBNA-1Dgly-ala.
The residual activity of EBNA-1DBox B/C and EBNA-
1DBox A/B/C may be due to the acidic carboxy-terminal
region of EBNA-1. This region was previously shown to
be dispensable for transcriptional activation by EBNA-1,
but largely responsible for activation by a truncated
EBNA-1 consisting of amino acids 450–641 (Ambinder et
al., 1991).
The inability of EBNA-1 derivatives lacking Box B/C to
ctivate transcription to the same extent as EBNA-1,
BNA-1Dgly-ala, and EBNA-1DBox A could not be ex-
plained by their relative levels of expression (Fig. 6) nor
by an inability of the cells expressing these EBNA-1
variants to support transcription from the TK promoter.
Cotransfection of a plasmid bearing the lacZ gene under
the control of the TK promoter with FR-TK-luc and expres-
sion plasmids for EBNA-1 and its derivatives yielded
similar levels of b-galactosidase activity (Table 1). We
lso considered the possibility that the transcriptional
ctivation defect of EBNA-1 derivatives lacking RGG Box
/C was due to a reduced ability of these proteins to bind
NA site-specifically. To address this possibility, we per-
TABLE 1
Transcriptional Activation by EBNA-1 and Derivatives
Lacking p32 Binding Site(s)
Effector
Fold transcriptional
activationa
b-Galactosidase
(A420 units/mg
protein/h)b
143
cells
NIH 3T3
cells
onec 1 1 3.39, 1.37 (2.38)
BNA-1 8.5 6 3.1 73 6 1.8 4.26, 1.92 (3.09)
BNA-1Dgly-ala 12 6 4.7 74 6 6.7 3.34, 2.23 (2.78)
BNA-1DBox A 9.7 6 4.1 43 6 8.5 3.17, 2.07 (2.62)
BNA-1DBox B/C 2.6 6 0.6 4.3 6 0.9 3.71, 2.70 (3.21)
BNA-1DBox A/B/C 2.3 6 0.3 3.2 6 1.7 4.43, 1.72 (3.07)
a 143 or NIH 3T3 cells were cotransfected with FR-TK-luc and pCMX
ncoding EBNA-1 or the derivative indicated and the relative light units
f luciferase activity per microgram of protein were measured and
xpressed as fold-transcriptional activation relative to cells transfected
ith FR-TK-luc and pCMX. The numbers are averages of three exper-
ments 6 standard deviations.
b In two of the experiments performed in 143 cells, cells were trans-
fected with pTKb-gal, FR-TK-luc, and an expression plasmid for the
protein indicated and the units of b-galactosidase activity per milligram
f protein per hour were measured (numbers in parentheses are the
verages of the two determinations).
c Cells transfected with pCMX.ormed a DNA coimmunoprecipitation assay with nu-
lear extracts prepared from HeLa cells transiently ex-
fressing EBNA-1, EBNA-1Dgly-ala, and the derivatives
acking Box A and/or Box B/C (Fig. 8). The 847-bp frag-
ent bearing oriP FR was specifically precipitated from
inding reactions containing EBNA-1, EBNA-1Dgly-ala,
nd derivatives lacking Box A and/or Box B/C and the
ther DNA fragments which lacked EBNA-1 binding sites
ere either not detected or present in relatively small
mounts compared to the 847-bp fragment. We conclude
hat regions of EBNA-1 that bind p32 participate in the
ranscriptional activation function of EBNA-1 and, as was
bserved in the stable oriP-plasmid maintenance assay,
eletion of amino acids 329–376 had a greater effect
han deletion of amino acids 34–57.
DISCUSSION
The results of chromatin immunoprecipitation experi-
ents shown here provide strong evidence for the local-
zation of p32 to oriP in vivo and thereby implicate p32 in
ne or more functions of oriP. It is likely that p32 is
ecruited to oriP through a direct interaction with EBNA-1,
s an EBNA-1–p32 complex can form in vitro in the
bsence of other proteins and DNA. Although both oriP
R and DS were present in immunoprecipitates prepared
ith anti-p32 antibodies, because of their proximity in the
BV genome and the ability of EBNA-1 to link FR and DS
e do not know whether p32 is targeted to one or to both
lements.
The finding that EBNA-1 recruits a mitochondrial pro-
ein to oriP was unexpected but may be explained by the
inding of nascent p32 by EBNA-1 in the cytoplasm
efore it engages the mitochondrial protein import ma-
hinery and subsequent movement of the complex into
he nucleus. This model is supported by the ability of
BNA-1 to cause the nuclear accumulation of p32 that
ither lacked the presequence or contained an amino-
erminal extension that prevented mitochondrial target-
ng, and it predicts that the p32 localized to oriP lacks the
resequence. Alternatively, it has been proposed that a
raction of p32 cycles between mitochondria and the
ucleus (Matthews and Russell, 1998) and EBNA-1 may
ind and retain p32 in the nucleus. A previous study
eported that epitope (FLAG)-tagged p32(81–282) local-
zed to the nucleus (Wang et al., 1997) whereas M45-
32(74–282) was only rarely observed in the nucleus of
ells not expressing EBNA-1 (Fig. 5). It is likely that the
ifferent subcellular locations of the two proteins is due
o differences in the epitope tags at their amino termini
nd the absence of the first seven amino acids of the
ature form of p32 from p32(81–282). Perhaps truncation
f the “A” alpha helix in p32(81–282) resulted in destabi-
ization of p32 monomer interactions and an accumula-
ion of monomers over dimers and trimers (Jiang et al.,
999). p32 monomers, but not trimeric p32, should beree to enter the nucleus by diffusion.
p32 is an evolutionarily conserved protein and, al-
cn ran o
152 VAN SCOY ET AL.though functional studies have been carried out in bud-
ding yeast, these studies have yielded conflicting data as
to its function. One group found that disruption of the p32
gene resulted in cells that grew poorly in medium con-
taining a nonfermentable carbon source, suggesting that
p32 expression is important for mitochondrial oxidative
phosphorylation (Muta et al., 1997), while another group
did not observe impaired growth of a p32-null strain
under the same conditions (Seytter et al., 1998). Although
identification of the function of p32 in mitochondria may
provide insight into the role it plays at oriP, it is possible
that p32 exhibits a novel function when recruited to oriP.
p32 can interact independently with two regions of
EBNA-1 containing related arginine- and glycine-rich re-
peat elements in a yeast two-hybrid assay (Wang et al.,
1997); however, these elements are not functionally
equivalent when examined in mammalian cells. The two
repeats located between amino acids 329 and 382 (Box
B/C), but not the single repeat located between residues
33 and 53 (Box A), were sufficient for the EBNA-1-medi-
ated nuclear targeting of p32. A role for p32 in the
transcriptional activation and stable plasmid mainte-
FIG. 8. EBNA-1 and its derivatives lacking the Gly-Gly-Ala repeats a
ipitation experiment was performed with nuclear extracts prepared fr
and 7), EBNA-1DBox A (lanes 8 and 9), EBNA-1DBox B/C (lanes 10 and
radiolabeled DNA fragments from pHEBo-2.1. Protein–DNA complexes
11, 13) or a control mAb (LFA1; lanes 2, 4, 6, 8, 10, 12). The input DNA
right. An 86-bp fragment that was also present in each binding reactio
that constitute oriP FR.nance functions of EBNA-1 is supported by our studies of
EBNA-1 derivatives lacking this element. EBNA-1DBoxB/C and EBNA-1DBox A/B/C were greatly reduced in
their abilities to activate transcription of FR-TK-luc and
support the replication and/or maintenance of an oriP-
plasmid and these defects correlated with the inability of
these EBNA-1 derivatives to cause the nuclear accumu-
lation of M45-p32(74–282). The results of Wang et al.
(1997) suggested that p32 plays a role in transcriptional
activation by EBNA-1 but, in contrast to the results pre-
sented here, concluded that both p32 binding sites are
required for EBNA-1 to increase transcription of a re-
porter gene linked to FR. This conclusion was based, in
part, upon the inability of an EBNA-1 derivative lacking
amino acids 40–60 (as well as most of the Gly-Gly-Ala
repeats) to activate transcription. It is possible that the
deletion of amino acids 34–57 (DBox A) did not remove
amino acids that, in the presence of Box B/C, can give
rise to a stable EBNA-1–p32 complex. A detailed analy-
sis of the p32 binding sites is needed to determine
whether Box B/C is sufficient for the formation of a stable
complex with p32.
p32 contains a region that can function as a transcrip-
tional activation domain (Wang et al., 1997; Yu et al.,
x A and/or Box B/C bind DNA site-specifically. A DNA coimmunopre-
La cells expressing EBNA-1 (lanes 4 and 5), EBNA-1Dgly-ala (lanes 6
NA-1DBox A/B/C (lanes 12 and 13), or no EBNA-1 (lanes 2 and 3) and
recipitated with either an anti-EBNA-1 mAb (mAb2B4; lanes 3, 5, 7, 9,
nts are shown in lanes 1 and 14 and their sizes are indicated on the
ff the gel. The 847-bp fragment contains the 20 EBNA-1 binding sitesnd Bo
om He
11), EB
were p
fragme1995b) and interacts with the general transcription factor
TFIIB in vitro (Yu et al., 1995a) and these properties,
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153EBNA-1 RECRUITS p32 TO oriPtogether with the acidic nature of p32, the localization of
p32 to oriP, and the transcriptional and replication de-
ects of EBNA-1 derivatives that fail to interact stably with
32 in vivo, strongly support a dual role for this cellular
rotein in EBNA-1-mediated transcriptional activation
nd DNA replication. There is widespread involvement of
ranscriptional elements in eukaryotic viral and cellular
NA replication (Li et al., 1998, and references therein)
nd information gathered from studies of these elements
uggest two nonexclusive roles for EBNA-1 and p32 in
he synthesis of oriP-plasmids. Nuclear factor 1 and the
cidic activation domains of VP16 and p53 can prevent
he inhibition of DNA replication by nucleosomes in vitro
Cheng and Kelly, 1989; Cheng et al., 1992; Li and
otchan, 1994) and EBNA-1-bound p32 may act similarly
o allow recognition of the origin by the cellular replica-
ion machinery. Alternatively, EBNA-1 may direct the cel-
ular replication machinery to oriP through protein–pro-
ein interactions. Both p53 and VP16 associate with the
0-kDa subunit of replication protein A through their
cidic activation domains (He et al., 1993; Li and
otchan, 1993) and the ability of mutant derivatives of
P16 to bind RPA correlates with their ability to activate
NA replication (He et al., 1993). EBNA-1 interacts di-
ectly with the 70-kDa subunit of RPA (Zhang et al., 1998)
nd potential contacts between p32 and RPA may con-
ribute to a functional interaction.
The interpretation of transcriptional activation and
lasmid replication/maintenance experiments with
BNA-1 derivatives that fail to cause the nuclear accu-
ulation of p32 is complicated by the apparent overlap
r coincidence of amino acids involved in binding p32
residues 40–60 and 325–376; Wang et al., 1997), the
ooping or linking of DNA containing EBNA-1 binding
ites (residues 54–89, 331–361, and 372–391; Mackey et
l., 1995), and elements with chromosome binding activ-
ty (residues 8–67, 72–84, and 328–375; Marechal et al.,
999). In addition, a host nucleolar protein has been
eported to bind EBNA-1 through amino acids 330–386
Shire et al., 1999). Further genetic analysis of these
egions of EBNA-1 will be required to gain a better
nderstanding of the contributions of these host proteins
nd activities to EBNA-1 function.
MATERIALS AND METHODS
ells
BL cells were grown in RPMI 1640 medium plus 10%
etal bovine serum. COS-7 cells were grown in Dulbec-
o’s modified Eagle’s medium (DMEM) plus 5% fetal
ovine serum. All other animal cells were grown as
onolayer cultures in DMEM plus 10% bovine calf se-
um. HeLa S3 cells were grown in spinner culture in
agle’s minimum essential medium with Earle’s salts
nd 5% bovine calf serum.lasmid and virus constructions
EBNA-1 was placed under control of the human cyto-
egalovirus (HCMV) immediate early gene enhancer
nd promoter by cloning the BglII fragment from pEBNA-
.2 containing the EBNA-1 orf (Hearing et al., 1992) into
he BamHI site of pE1A-CMX (Obert et al., 1994) to create
E1A/CMX-EBNA1. Ad/CMV-EBNA1, an adenovirus
BNA-1-expression vector, was obtained by selecting
ecombinants between pE1A/CMX-EBNA1 and Ad5
l309 (Schmidt and Hearing, 1999). pCMX/EBNA-1 was
reated by inserting the BglII fragment from pEBNA-1.2
ontaining the EBNA-1 orf into the BamHI site of pCMX
Umesono et al., 1991). The orf for EBNA-1 lacking all but
2 residues of the glycine-glycine-alanine repeat was
mplified by PCR using p367 (Yates and Camiolo, 1988)
s template and cloned into the BamHI site of pCMX to
reate pCMX/EBNA-1Dgly-ala. A two-step PCR-based
trategy (Freeman et al., 1996) using p367 as template
as used to obtain expression plasmids for EBNA-1
erivatives lacking the glycine-glycine-alanine repeats
nd amino acids 34–57 (pCMX/EBNA-1DBox A) or amino
cids 329–376 (pCMX/EBNA-1DBox B/C). The same
trategy, employing pCMX/EBNA-1DBox A as template,
as used to construct pCMX/EBNA-1DBox A/B/C. pE1A-
MX/p32(74–282) encodes p32 amino acids 74–282 with
n amino-terminal extension of 17 amino acids contain-
ng the adenovirus E4-6/7 M45 epitope (Obert et al.,
994). pGEX/p32, encoding a GST fusion protein with
uman p32 amino acids 74–282, was created by PCR-
mplification and insertion of the fragment into the EcoRI
ite of pGEX-KG (Guan and Dixon, 1991).
rotein purification
HeLa S3 cells in spinner culture (5–6 3 105 cells/ml)
ere infected with Ad/CMV-EBNA1 at 200 particles/cell
nd harvested 24 h later. EBNA-1 was purified from 9 3
08 infected cells by heparin–agarose (Frappier and
O’Donnell, 1991b) and DNA affinity (Hearing et al., 1992)
chromatography. GST-p32(74–282) was expressed in E.
coli, purified from cell lysates, and released from GST
with thrombin as described (Guan and Dixon, 1991).
Antibodies
An anti-EBNA-1 serum was obtained by immunization
of rabbits with EBNA-1 purified from insect cells (Hearing
et al., 1992). Bacterially produced p32(74–282) was fur-
ther purified on SDS–gels prior to injection into chickens.
Antibodies were purified from eggs from one seroposi-
tive hen as previously described (Jensenius et al., 1981).
For preparation of anti-p32 mAbs, Balb-C mice were
immunized with recombinant p32 (Krainer et al., 1991)
purified by preparative SDS–PAGE. Standard procedures
(Harlow and Lane, 1998) were used for immunization,
generation of hybridomas with NS-1 myeloma cells, and
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154 VAN SCOY ET AL.mAb production in ascites fluid at the Cold Spring Harbor
Laboratory Monoclonal Antibody Facility.
Coimmunoprecipitation assays
COS-7 cells (7 3 105) were transfected with 10 mg of
salmon sperm DNA with or without 10 mg of the EBNA-1
xpression plasmid p371 (Yates and Camiolo, 1988) by
he calcium phosphate coprecipitation method and har-
ested 38 h after addition of the precipitates. Cells were
ysed with 1.0 ml of 0.5% NP-40, 50 mM HEPES–NaOH
pH 7.5), 100 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1 mM
MSF, sonicated, and clarified by centrifugation at
0,000g, 15 min at 4°C. One-quarter of each lysate was
ncubated with 6 ml of rabbit anti-EBNA-1 serum for 1 h
on ice. Subsequently, 50 ml of a 50-mg protein A–Sepha-
ose/ml suspension was added and incubation was con-
inued for 30 min at 4°C with mixing. Beads were washed
our times with lysis buffer and boiled in SDS–gel sample
uffer. EBV-positive and -negative BL cells (1.3 3 108) and
93 cells (1 3 107) 20 h postinfection with Ad/CMV-
BNA1 or a control virus (dl356-E2-CAT-LSATF) were
ashed twice with PBS plus 1 mM PMSF, lysed with 1.0%
P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris–HCl
pH 8.0], 150 mM NaCl, sonicated, clarified by centrifu-
ation, and immunoprecipitated with 3 ml of rabbit pre-
mmune serum or anti-EBNA1 serum as described
bove.
Purified EBNA-1 and p32 (0.5 mg of each protein in 50
ml of NP-40 lysis buffer, 1 mM PMSF) were incubated
individually at 30°C in the presence or absence of either
ethidium bromide (50 mg/ml) or RNase A (100 mg/ml).
Appropriate proteins or buffer were combined and pre-
cipitated with anti-EBNA-1 serum. Ethidium bromide (50
mg/ml) was included in the first three washes of the
sample pretreated with the dye.
Immunoblots
Samples were electrophoresed on either SDS–10%
polyacrylamide gels (Figs. 1C and 6) or SDS–5% to 20%
gradient polyacrylamide gels (Figs. 1A and 1B), trans-
ferred to nitrocellulose, and blotted with antibodies using
standard procedures. Anti-EBNA-1 serum and p32 anti-
bodies were diluted 1:3200 and 1:5000, respectively.
mAb2B4 hybridoma culture supernatant (Gra¨sser et al.,
1994) was diluted 1:20. Horseradish-peroxidase-coupled
secondary antibodies were diluted 1:2500. Immunoblots
were developed with SuperSignal Chemiluminescent
Substrate (Pierce).
Nuclear extracts
HeLa cells (1.3 3 105 cells/60-mm plate) were trans-
ected with 5 mg of pCMX encoding wild-type or mutant
erivatives of EBNA-1 using FuGENE6 (Roche Molecular
iochemicals) and harvested 48 h later. Washed cells
ere lysed by the addition of 0.2 ml of 10 mM HEPES–
C
TaOH (pH 7.4), 10 mM KCl, 0.75 mM spermidine, 0.75
M spermine, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM
b-mercaptoethanol, 0.1% NP-40, 0.5 mM PMSF, 2.5 mM
benzamidine, 10 mg leupeptin/ml, and 10 mg pepstatin/
l. The nuclei were immediately pelleted in a microcen-
rifuge for 15 s, suspended in 0.02 ml of 20 mM HEPES–
aOH (pH 7.9), 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2,
0 mM b-mercaptoethanol, 0.5 mM PMSF, 2.5 mM ben-
amidine, 10 mg leupeptin/ml, and 10 mg pepstatin/ml,
nd incubated on ice for 30 min. The extracted nuclei
ere removed from the extracts by centrifugation.
NA coimmunoprecipitation assays
Plasmids bearing FR and DS (pBS/oriP) or FR alone
pHEBo-2.1; M. Koons and J. Hearing, unpublished data)
ere digested with NcoI and XhoI (pBS/oriP) or SalI and
NcoI (pHEBo-2.1) and the resulting DNA fragments were
end-labeled with Klenow DNA polymerase and
[a-32P]dATP. End-labeled DNA fragments (5 ng total)
ere combined with purified proteins or nuclear extract
n 20 mM HEPES–NaOH (pH 7.9), 5 mM MgCl2, 300 mM
aCl, 1 mM DTT, 0.1% NP-40, 5.3% glycerol, 1.5 mg
ingle-stranded salmon sperm DNA /ml, 1.5 mg double-
tranded salmon sperm DNA /ml, and 50 mg BSA/ml in a
final volume of 20 ml. After 30 min of incubation at room
emperature, the binding reactions were diluted 10-fold
ith 20 mM HEPES–NaOH (pH 7.5), 130 mM NaCl, 5 mM
gCl2, 0.1% NP-40, and incubated on ice for 30 min with
ybridoma culture supernatant containing mAb to either
he a subunit of LFA-1 (M17/4.4.11.9; American Type Cul-
ure Collection) or EBNA-1 (1H4; Gra¨sser et al., 1994) or
he ascites fluid containing mAb to p32. Immune com-
lexes were precipitated with protein G–Sepharose,
ashed with 20 mM HEPES–NaOH (pH 7.5), 160 mM
aCl, 5 mM MgCl2, 0.1% NP-40, released by heating to
0°C for 3 min in 10 mM Tris–HCl (pH 8.0), 1 mM EDTA,
% SDS, and electrophoresed on 1% agarose gels. Quan-
itation was performed with a Molecular Dynamics Storm
60 phosphorimager.
hromatin immunoprecipitations
Raji cells at ;2.5 3 105 cells/ml were labeled with 0.5
mCi [3H]thymidine (60 Ci/mmol; ICN Radiochemicals)/ml
or 24–30 h. One-tenth volume of 11% formaldehyde in 50
M HEPES–NaOH (pH 8.0), 0.1 M NaCl, 1 mM EDTA, 1
M EGTA, was added to the cultures and the cells were
ixed for 14–16 h at 4°C. Chromatin was isolated by
onication and purified by centrifugation on CsCl–Sarko-
yl gradients as described (Orlando et al., 1997). Aliquots
of chromatin containing 60 mg DNA were subjected to
immunoprecipitation and prepared for PCR as described
(Meluh and Broach, 1999). PCR primers were 59 GG-
GAATTCATGGACATCCAGTCTTTACG 39 and 59 GGCG-AAGCTTTCATCCTGGAGC 39 (DS; 792 bp), 59 CGGAAT-
CATGTCTGACGAGG 39 and 59 GCGGATCCTATGTTC-
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155EBNA-1 RECRUITS p32 TO oriPCACCGTGGGTCC 39 (EBNAorf; 287 bp). Serial dilutions
of the input DNA and precipitated DNA (2- or 2.5-fold)
were amplified to identify template concentrations within
the linear range of the assay for quantitation. PCR prod-
ucts were resolved on agarose gels, stained with
ethidium bromide, and photographed with Polaroid 665
film and scans of the negatives were quantified with NIH
Image.
Luciferase assays
Cells (1.5 3 105 cells per 60-mm dish) were transfected
ith 1 mg reporter plasmid (TK-luc or FR-TK-luc; Middle-
on and Sugden, 1992) and 50 ng effector plasmid (pCMX
r derivatives encoding wild-type or mutant EBNA-1) by
alcium phosphate coprecipitation and analyzed after
0 h incubation using Promega’s Luciferase Assay Sys-
em. In two experiments using 143 cells, 1 mg of the
eporter plasmid pTKbgal (Park et al., 1994), 1 mg of
luciferase reporter plasmid, and 50 ng of effector plasmid
were introduced into duplicate cultures using FuGENE6.
One set of cultures was analyzed for luciferase activity
following 48 h of incubation. Extracts from duplicate
cultures were prepared by four freeze–thaw cycles in 100
ml of 10 mM Tris–HCl (pH 7.5), 10 mM EDTA, 25 mM
sucrose, and 1 mM PMSF, clarified by centrifugation, and
assayed for b-galactosidase activity as previously de-
scribed (Bartel et al., 1993).
IF staining
Cells, transfected 24–48 h prior to staining, were
washed with PBS and fixed with 4% paraformaldehyde in
PBS for 10 min. The cells were washed with PBS, incu-
bated for 20 min in PBS with 50 mM glycine, and perme-
abilized with 0.1% Triton X-100 in PBS. Primary antibodies
were diluted 1:4 (mAb M45) or 1:200 (rabbit anti-EBNA-1
antibodies) in PBS. Fluoroscein isothiocyanate (FITC)-
conjugated goat anti-mouse IgG, tetramethylrhodamine
isothiocyanate (TRITC)-conjugated goat anti-mouse IgG,
and goat anti-rabbit IgG (Zymed Laboratories) were di-
luted 1:250 in PBS.
DNA replication assay
HeLa cells (2 3 105 cells/60-mm dish) were cotrans-
fected with 2.5 mg pHEBo-1.1 (Hearing et al., 1992) and
2.5 mg pCMX or derivatives encoding wild-type or mutant
BNA-1 using FuGENE6. The cells were trypsinized 18 h
fter the addition of plasmid DNA and seeded in one
00-mm dish per original 60-mm dish for 72 h further
ncubation. The populations underwent approximately
our cell divisions after the addition of plasmid DNA.
ow-molecular-weight DNA was prepared and one-third
f each sample was analyzed as previously described
Hearing et al., 1992). Replication products from three
ndependent experiments were quantitated with a Mo-
ecular Dynamics Storm 860. The efficiencies with whichBNA-1 derivatives supported the replication of pHEBo-
.1 (e) or retained the plasmid in the cell (b) per cell
eneration compared to EBNA-1 were calculated using
he formula
Ni
No
5 S @~1 1 e! i 2 ~1 2 e! i #2 i Db i,
here Ni is the amount of replicated plasmid DNA
present after i cell generations in cells expressing an
EBNA-1 derivative and No is the amount of plasmid DNA
resent after i cell generations in cells expressing
BNA-1.
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